Case Report: Durable response to PD-1 blockade after failure of ALK-targeted therapy and chemoimmunotherapy in ALK-positive large B-cell lymphoma
BackgroundAnaplastic lymphoma kinase–positive large B-cell lymphoma (ALK+ LBCL) is an exceedingly rare and aggressive subtype of B-cell non-Hodgkin lymphoma, comprising less than 1% of all LBCL cases. These tumors often exhibit resistance to standard chemoimmunotherapy and targeted approaches, resul...
Kaydedildi:
| Asıl Yazarlar: | , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Frontiers Media S.A.
2026-01-01
|
| Seri Bilgileri: | Frontiers in Hematology |
| Konular: | |
| Online Erişim: | https://www.frontiersin.org/articles/10.3389/frhem.2025.1683981/full |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|